MedPath
Found 12 clinical trials|View Analysis
Sort by:

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2
Active, not recruiting
Conditions
Brenner Tumor
Malignant Pleural Effusion
Ovarian Endometrioid Adenocarcinoma
Recurrent Fallopian Tube Cancer
Recurrent Primary Peritoneal Cavity Cancer
Ovarian Clear Cell Cystadenocarcinoma
Stage IIIC Fallopian Tube Cancer
Malignant Ascites
Ovarian Mixed Epithelial Carcinoma
Recurrent Ovarian Epithelial Cancer
Interventions
Drug: metformin hydrochloride
Drug: placebo
Drug: Chemotherapy
First Posted Date
2014-04-24
Last Posted Date
2024-07-31
Lead Sponsor
University of Chicago
Target Recruit Count
110
Registration Number
NCT02122185
Locations
🇺🇸

Mitchell Cancer Institute - University of South Alabama, Mobile, Alabama, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 7 locations

Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer

Not Applicable
Completed
Conditions
Cancer Survivor
Stage IIA Ovarian Epithelial Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IB Ovarian Epithelial Cancer
Stage IIIB Ovarian Epithelial Cancer
Stage IIB Ovarian Epithelial Cancer
Stage IIC Ovarian Epithelial Cancer
Stage IA Ovarian Epithelial Cancer
Stage IC Ovarian Epithelial Cancer
Stage IIIC Ovarian Epithelial Cancer
Interventions
Other: active surveillance
Other: follow-up care
Other: questionnaire administration
First Posted Date
2014-03-10
Last Posted Date
2017-09-28
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
14
Registration Number
NCT02082470
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Phase 1
Withdrawn
Conditions
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IA Fallopian Tube Cancer
Stage IA Ovarian Epithelial Cancer
Stage IA Primary Peritoneal Cavity Cancer
Stage IB Fallopian Tube Cancer
Stage IB Ovarian Epithelial Cancer
Stage IB Primary Peritoneal Cavity Cancer
Stage IC Fallopian Tube Cancer
Interventions
Drug: IDO1 inhibitor INCB024360
Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2013-11-13
Last Posted Date
2013-12-18
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT01982487

Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer

Not Applicable
Withdrawn
Conditions
Stage IIIB Ovarian Epithelial Cancer
Stage III Pancreatic Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIA Ovarian Germ Cell Tumor
Stage IV Pancreatic Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Pancreatic Cancer
Stage IIIB Ovarian Germ Cell Tumor
Stage IIIC Ovarian Epithelial Cancer
Stage IIIC Ovarian Germ Cell Tumor
Interventions
Procedure: quality-of-life assessment
Other: palliative care
Behavioral: educational intervention
Behavioral: telephone-based intervention
Other: questionnaire administration
First Posted Date
2013-08-22
Last Posted Date
2014-12-23
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT01927393
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Not Applicable
Completed
Conditions
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Bladder Cancer
Stage IIB Cervical Cancer
Stage IIC Ovarian Epithelial Cancer
Stage IIIA Cervical Cancer
Stage IIIA Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Uterine Sarcoma
Stage IIIC Rectal Cancer
Stage IV Ovarian Epithelial Cancer
Interventions
Other: educational intervention
Behavioral: telephone-based intervention
Procedure: quality-of-life assessment
Other: questionnaire administration
First Posted Date
2013-05-03
Last Posted Date
2020-01-23
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
200
Registration Number
NCT01846520
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer

Phase 2
Completed
Conditions
Ovarian Sarcoma
Stage I Uterine Sarcoma
Stage I Vulvar Cancer
Stage IA Ovarian Epithelial Cancer
Stage IC Fallopian Tube Cancer
Stage IIA Fallopian Tube Cancer
Stage IIA Ovarian Germ Cell Tumor
Stage IIIA Ovarian Germ Cell Tumor
Stage IIIB Endometrial Carcinoma
Stage IIIB Fallopian Tube Cancer
Interventions
Other: behavioral, psychological or informational intervention
First Posted Date
2013-01-10
Last Posted Date
2018-05-30
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
100
Registration Number
NCT01764802
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer

Phase 3
Conditions
Ovarian Neoplasms
Interventions
Procedure: Cytoreductive Surgery and HIPEC
Procedure: CRS alone
First Posted Date
2012-06-26
Last Posted Date
2014-08-28
Lead Sponsor
A.O. Ospedale Papa Giovanni XXIII
Target Recruit Count
94
Registration Number
NCT01628380
Locations
🇮🇹

A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna - Bologna (Bo), Bologna, Bo, Italy

🇩🇪

Jena University Hospital, Jena, Germany

🇮🇹

A.O. Universitaria Di Parma - Parma (Pr) Oncologia Chirurgica, Parma, Pr, Italy

and more 2 locations

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1
Completed
Conditions
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IIA Fallopian Tube Cancer
Stage IIA Ovarian Epithelial Cancer
Stage IIA Primary Peritoneal Cavity Cancer
Stage IIB Fallopian Tube Cancer
Stage IIB Ovarian Epithelial Cancer
Stage IIB Primary Peritoneal Cavity Cancer
Stage IIC Fallopian Tube Cancer
Interventions
Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Drug: sirolimus
Other: laboratory biomarker analysis
Biological: sargramostim
First Posted Date
2012-02-20
Last Posted Date
2020-03-27
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
7
Registration Number
NCT01536054
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIC Fallopian Tube Cancer
Stage IIIC Ovarian Epithelial Cancer
Stage IV Primary Peritoneal Cavity Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIA Primary Peritoneal Cavity Cancer
Stage IIIB Fallopian Tube Cancer
Stage IIIB Primary Peritoneal Cavity Cancer
Interventions
Drug: sunitinib malate
Other: laboratory biomarker analysis
First Posted Date
2006-10-13
Last Posted Date
2015-01-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT00388037
Locations
🇨🇦

National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Phase 1
Completed
Conditions
Recurrent Cervical Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Vaginal Cancer
Recurrent Vulvar Cancer
Stage III Vaginal Cancer
Stage IIIA Cervical Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIB Ovarian Epithelial Cancer
Stage IIIB Vulvar Cancer
Stage IIIC Ovarian Epithelial Cancer
Interventions
Drug: triapine
Other: laboratory biomarker analysis
Radiation: external beam radiation therapy
Radiation: brachytherapy
Drug: cisplatin
Other: pharmacological study
First Posted Date
2006-06-12
Last Posted Date
2013-01-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00335998
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath